Literature DB >> 15337408

Treatment of stable chronic obstructive pulmonary disease.

Stephen I Rennard1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a readily diagnosable disorder that responds to treatment. Smoking cessation can reduce symptoms and prevent progression of disease. Bronchodilator therapy is key in improvement of lung function. Three classes of bronchodilators-beta agonists, anticholinergics, and theophylline-are available and can be used individually or in combination. Inhaled glucocorticoids can also improve airflow and can be combined with bronchodilators. Inhaled glucocorticoids, in addition, might reduce exacerbation frequency and severity as might some bronchodilators. Effective use of pharmacotherapy in COPD needs integration with a rehabilitation programme and successful treatment of co-morbidities, including depression and anxiety. Treatment for stable COPD can improve the function and quality of life of many patients, could reduce admissions to hospital, and has been suggested to improve survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337408     DOI: 10.1016/S0140-6736(04)16941-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

1.  Attributions about cause of illness in chronic obstructive pulmonary disease.

Authors:  Karin F Hoth; Frederick S Wamboldt; Russell Bowler; Barry Make; Kristen E Holm
Journal:  J Psychosom Res       Date:  2010-12-23       Impact factor: 3.006

2.  How long can I go on like this? Dying from cardiorespiratory disease.

Authors:  Richard Lehman
Journal:  Br J Gen Pract       Date:  2004-12       Impact factor: 5.386

Review 3.  [Chronic bronchitis, COPD].

Authors:  H R Wirtz
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

Review 4.  ABC of chronic obstructive pulmonary disease. Pharmacological management--oral treatment.

Authors:  Graeme P Currie; Daniel K C Lee; Brian J Lipworth
Journal:  BMJ       Date:  2006-06-24

Review 5.  COPD exacerbations.5: management.

Authors:  R Rodríguez-Roisin
Journal:  Thorax       Date:  2006-06       Impact factor: 9.139

Review 6.  PDE4 inhibitors: current status.

Authors:  D Spina
Journal:  Br J Pharmacol       Date:  2008-07-28       Impact factor: 8.739

7.  Behavioral and characterological self-blame in chronic obstructive pulmonary disease.

Authors:  Melissa R Plaufcan; Frederick S Wamboldt; Kristen E Holm
Journal:  J Psychosom Res       Date:  2011-12-07       Impact factor: 3.006

8.  The effects of CXCL10 polymorphisms on COPD susceptibility.

Authors:  Yan Wang; Qipeng Zhou; Lian Dong; Mingmei Xiong; Hua Jiang; Meihua Guo; Li Zhao; Liang Yuan; Ziying Li; Hanwei Liu; Jian Wang; Nanshan Zhong; Wenju Lu
Journal:  Mol Genet Genomics       Date:  2017-12-28       Impact factor: 3.291

9.  Lack of association between the G+2044A polymorphism of interleukin-13 gene and chronic obstructive pulmonary disease: a meta-analysis.

Authors:  Lian Duan; Rui Liang; Zhendong Wang; Lei Lei; Lianhong Jin; Jingling Shen; Shoude Jin
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

Review 10.  Pharmacological treatment of chronic obstructive pulmonary disease.

Authors:  Paolo Montuschi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.